Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glimepiride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 known ✓ | Q09428 | 2/20 | 0.43 |
| ▸ | KCNJ11 known ✓ | Q14654 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 3/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 2/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | PPARG | P37231 | 8/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glimepiride SCHEMBL16084 | 1.00 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL16086 | 1.00 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL14965363 | 1.00 | CYP2C9 (1.00) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL5081711 | 0.99 | CYP2C9 (0.98) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL20877218 | 0.99 | CYP2C9 (0.98) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL6381985 | 0.98 | CYP2C9 (0.95) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL11185683 | 0.93 | CYP2C9 (0.86) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL23782324 | 0.93 | CYP2C9 (0.85) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| Glimepiride SCHEMBL28086181 | 0.93 | CYP2C9 (0.85) | CYP2C9ABCC3ABCC4ABCB11HIF1A | |
| SCHEMBL11189249 | 0.92 | CYP2C9 (0.86) | CYP2C9ABCC3ABCC4ABCB11HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016334-A1 | Multi-Cartridge Fluid Delivery Device | ZEALAND PHARMA A/S (DK) | 2022-01-20 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200046897-A1 | Multi-Cartridge Fluid Delivery Device | VALERITAS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| CN-110511993-A | For detecting primer sets, application, product and the method for children's drug metabolism associated SNP positions | JIANGSU XIANSHENG MEDICAL INSTR CO LTD | 2019-11-29 | — | — | CN | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20180028743-A1 | Multi-Cartridge Fluid Delivery Device | VALERITAS, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-2982399-B1 | MULTI-CARTRIDGE FLUID DELIVERY DEVICE | VALERITAS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9687599-B2 | Multi-cartridge fluid delivery device | VALERITAS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3137065-A2 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES | Pharnext (FR) | 2017-03-08 | — | — | EP | disclosed |
| EP-3062782-A1 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL | Pharnext (FR) | 2016-09-07 | — | — | EP | disclosed |
| US-8361053-B2 | Multi-cartridge fluid delivery device | VALERITAS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130012433-A1 | METHOD FOR REDUCING CARDIOVASCULAR MORBIDITY AND MORTALITY IN PREDIAETIC PATIENTS AND PATIENTS WITH TYPE 2 DIABETES | AVENTIS PHARMACEUTICALS INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110281793-A1 | Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes | AVENTIS PHARMACEUTICALS INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7977310-B2 | Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes | AVENTIS PHARMACEUTICALS INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090240232-A1 | MULTI-CARTRIDGE FLUID DELIVERY DEVICE | VAKERUTAS,LLC | 2009-09-24 | — | — | US | disclosed |
| EP-2005309-A2 | MULTI-CARTRIDGE FLUID DELIVERY DEVICE | Valeritas, LLC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080287343-A1 | METHOD FOR REDUCING CARDIOVASCULAR MORBIDITY AND MORTALITY IN PREDIABETIC PATIENTS AND PATIENTS WITH TYPE 2 DIABETES | AVENTIS PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7405196-B2 | Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes | AVENTIS PHARMACEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| CN-101180062-A | Compound preparation for treating diabetes mellitus | HUAIBEI HUIKE DRUG CO LTD (CN) | 2008-05-14 | — | — | CN | disclosed |
| WO-2007115039-A2 | MULTI-CARTRIDGE FLUID DELIVERY DEVICE | VALERITAS, LLC (US) | 2007-10-11 | — | — | WO | disclosed |